GenBio AI develops an AI-Driven Digital Organism (AIDO), an integrated system of multiscale foundation models designed to predict, simulate, and program biology across every scale. The company's core focus is engineering a virtual cell - a computational model of life's fundamental unit - to make biological systems computable and programmable rather than opaque to analysis.
The company operates from headquarters in Palo Alto, California, with satellite laboratories in Paris and Abu Dhabi, supported by a global team combining expertise in artificial intelligence, computational biology, machine learning, and molecular science. GenBio AI's technical approach spans multiscale modeling, foundation models, biological simulation, and biological prediction, targeting applications in drug discovery, healthcare, and fundamental research.
The underlying premise animating the company's work is that curing disease can be reframed as an engineering problem rather than a decades-long experimental undertaking. This reflects a conviction that sufficiently sophisticated computational models of biological systems can reduce the unpredictability and time required to develop new therapeutics and understand fundamental biological processes.
